Apellis Pharmaceuticals to Host Conference Call on May 4, 2023, to Discuss First Quarter 2023 Financial Results
Apellis Pharmaceuticals (Nasdaq: APLS) announced a conference call and webcast to discuss its first quarter 2023 financial results scheduled for May 4, 2023, at 4:30 p.m. ET.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Summary
Apellis Pharmaceuticals (Nasdaq: APLS) announced a conference call and webcast to discuss its first quarter 2023 financial results scheduled for May 4, 2023, at 4:30 p.m. ET. Interested participants must pre-register for the call. The event will be accessible via the company’s website, where a replay will be available for 30 days post-event. As a leader in complement medicine, Apellis focuses on innovative therapies for serious diseases, including geographic atrophy, a major cause of blindness. With a strong pipeline of nearly a dozen clinical and pre-clinical programs, the company is committed to maximizing the potential of targeting C3. For further details, visit their official website.
Positive
- Strong pipeline with nearly a dozen clinical and pre-clinical programs.
- Leader in complement medicine, introducing the first therapy for geographic atrophy.
Negative
- None.
Details
News Market Reaction – APLS
The recorded move for APLS in the trading session of this news was -2.24%.
Data tracked by StockTitan Argus. Session date unavailable.
AI-generated analysis. How Rhea-AI works. Not financial advice.
WALTHAM, Mass., April 27, 2023 (GLOBE NEWSWIRE) -- Apellis Pharmaceuticals, Inc. (Nasdaq: APLS), a global biopharmaceutical company and leader in complement, today announced that the company will host a conference call and webcast to discuss its first quarter 2023 financial results on Thursday, May 4, 2023, at 4:30 p.m. ET.
To access the live call by phone, please pre-register for the call here. A live audio webcast of the event and accompanying slides may also be accessed through the “Events and Presentations” page of the “Investors and Media” section of the company’s website. A replay of the webcast will be available for 30 days following the event.
About Apellis
Apellis Pharmaceuticals, Inc. is a global biopharmaceutical company that combines courageous science and compassion to develop life-changing therapies for some of the most challenging diseases patients face. We ushered in the first new class of complement medicine in 15 years and now have two approved medicines targeting C3. These include the first and only therapy for geographic atrophy, a leading cause of blindness around the world. With nearly a dozen clinical and pre-clinical programs underway, we believe we have only begun to unlock the potential of targeting C3 across many serious diseases. For more information, please visit http://apellis.com or follow us on Twitter and LinkedIn.
Investor Contact:
Meredith Kaya
meredith.kaya@apellis.com
617.599.8178
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.